Fig. 3From: Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancerTornado diagram representing results of one-way sensitivity analysis. Model parameters were varied within the range of values shown in parenthesis. QALY: quality-adjusted life year; PF: progression-free; PD: progressed diseaseBack to article page